• Agustin de la Calle
  • CBO
  • Eutilex Co.Ltd

Curriculum Vitae

Education

Massachusetts Institute Of Technology, Cambridge, MA Chemistry Post Doc
Freie Universität Berlin & Harvard Medical School, BOSTON, MA Biochemistry Ph.D.
Freie Universität Berlin Physics M.S.
Freie Universität Berlin Physics B.S.

Professional Experience

Dr. de la Calle is our Chief Business Officer. His proven success record spans more than 20 years during which time he negotiated more than fifteen deals in the global biotech space. His expertise is working internationally to form strategic partnerships in the areas of platform technologies, therapeutics, and diagnostics.

Previously he was appointed as Executive Consultant by a division of the South Korean government supporting in a central role Korean companies in successful market penetration, product partnering and fund raising in USA and Europe. In a prior role, he was head of business development at Innate Pharma, S.A. (France), where he led the negotiating team and advanced the closing of alliances and licenses that proved to be of strategic importance both for the company’s successful IPO in 2006 and for its commercial product launch in early 2007. He was Director of business development at Micromet where he helped start the licensing business of the scFv IP portfolio. Micromet achieved remarkable success with the BiTE approach and was acquired by Amgen for $1.2B.

Research Interests

Honors & Awards

Publications